These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10827368)

  • 1. High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial.
    Marrouche NF; Reddy RK; Wittkowsky AK; Bardy GH
    Am Heart J; 2000 Jun; 139(6):E8-11. PubMed ID: 10827368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.
    Okishige K; Nishizaki M; Azegami K; Igawa M; Yamawaki N; Aonuma K;
    Am Heart J; 2000 Sep; 140(3):e13. PubMed ID: 10966544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
    Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
    Frick M; Darpö B; Ostergren J; Rosenqvist M
    Eur Heart J; 2000 Jul; 21(14):1177-85. PubMed ID: 10924301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II.
    Okishige K; Fukunami M; Kumagai K; Atarashi H; Inoue H;
    Circ J; 2006 Jun; 70(6):657-61. PubMed ID: 16723783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
    Farkowski MM; Maciag A; Dabrowski R; Pytkowski M; Kowalik I; Szwed H
    Trials; 2012 Sep; 13():162. PubMed ID: 22967497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators.
    Atarashi H; Inoue H; Hiejima K; Hayakawa H
    Am J Cardiol; 1996 Sep; 78(6):694-7. PubMed ID: 8831412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
    Stroobandt R; Stiels B; Hoebrechts R
    Am J Cardiol; 1997 Feb; 79(4):418-23. PubMed ID: 9052343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).
    Dąbrowski R; Syska P; Mączyńska J; Farkowski M; Sawicki S; Kubaszek-Kornatowska A; Michałek P; Kowalik I; Szwed H; Hryniewiecki T
    Trials; 2020 May; 21(1):397. PubMed ID: 32398047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
    Naegeli B; Straumann E; Bertel O
    Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
    Crijns HJ; Van Gelder IC; Walfridsson H; Kulakowski P; Rónaszéki A; Dedek V; Malm A; Almgren O
    Heart Rhythm; 2006 Nov; 3(11):1321-31. PubMed ID: 17074639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
    Benditt DG; Williams JH; Jin J; Deering TF; Zucker R; Browne K; Chang-Sing P; Singh BN
    Am J Cardiol; 1999 Aug; 84(3):270-7. PubMed ID: 10496434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
    Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
    Glatter K; Yang Y; Chatterjee K; Modin G; Cheng J; Kayser S; Scheinman MM
    Circulation; 2001 Jan; 103(2):253-7. PubMed ID: 11208685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
    Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter.
    Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rosenshtraukh LV; Chazov EI
    J Cardiovasc Pharmacol; 2014 Sep; 64(3):247-55. PubMed ID: 24785342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
    Imai S; Saito F; Takase H; Enomoto M; Aoyama H; Yamaji S; Yokoyama K; Yagi H; Kushiro T; Hirayama A
    Circ J; 2008 May; 72(5):709-15. PubMed ID: 18441448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.